RecruitingNCT06752941
LOW-PV Continuation
Studying Polycythemia vera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Principal Investigator
- TIZIANO BARBUI, MDFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Enrollment
- 36 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2024 – 2026
Study locations (13)
- Fondazione IRCCS Policlinico San Matteo, Divisione Ematologia, Pavia, Lombardy, Italy
- Ospedale Borgo Roma, Divisione Ematologia, Verona, Veneto, Italy
- ASST Papa Giovanni XXIII, SC Ematologia, Bergamo, Italy
- Policlinico S. Orsola - Malpighi, UO Ematologia, Bologna, Italy
- Azienda Ospedaliero Universitaria Careggi, SOD Ematologia, Florence, Italy
- Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, SC Ematologia, Milan, Italy
- Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo, Milan, Italy
- Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo, Naples, Italy
- Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy
- Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy
- A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U, Torino, Italy
- ASST Sette Laghi, Ospedale di Circolo e F. Macchi, Divisione UO Ematologia, Varese, Italy
- Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia, Vicenza, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06752941 on ClinicalTrials.govOther trials for Polycythemia vera
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation
- RECRUITINGPHASE2NCT07232290Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE2NCT06985147A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Disc Medicine, Inc
- RECRUITINGNCT06743035Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyiOMEDICO AG
- RECRUITINGPHASE3NCT06093672Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraItalfarmaco
- RECRUITINGPHASE1NCT06752746A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraMabwell (Shanghai) Bioscience Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06033586Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraProtagonist Therapeutics, Inc.
- RECRUITINGPHASE2NCT05870475Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVInstitute of Hematology & Blood Diseases Hospital, China